Post by Hot Christian Stocks on Apr 8, 2014 5:21:33 GMT -5
Introducing
OTC Pink: (PIHN)
PIHN is our Cannabis Alert for Tuesday. Cannabis stocks are driving the Micro-Cap Market right now and they will probably continue to drive the market for months to come. PIHN has recently acquired exclusive rights to ProCannas®. The Company also released some very strong news Pre-Market on Monday and we think this news is only the beginning.
Polaris International Holdings, Inc. (OTCPINK: PIHN) is pleased to announce they have entered into an exclusive agreement with Longevity Holdings, LLC for the ProCannas® product line. The agreement grants the sole rights to sell, distribute and market the provisional patent-pending formulation of Longevity Holding, LLC cannabis oil. The ProCannas® line is unique due to the blend of cannabinoids, vitamins, antioxidants, and other proven ingredients to be used for medicinal purposes. The full ProCannas® Line will include liquid drops for ingestion, tablets, and transdermal patches. The oils used in these formulations are high quality pharmaceutical grade and will only be available through licensed participating physicians.
Read full press release here and also below
PLEASE NOTE: THE THC HAS BEEN REMOVED FROM ALL PROCANNAS PRODUCTS
ProCannas offers its first-generation Cannatrol™ product line only through our trained participating physicians. Because of the purity and maximum strength of our formulations, they are best offered to patients under professional guidance. However, they will not require a formal prescription in the United States.
During the course of the extensive scientific research, conducted by noted universities and healthcare oriented organizations, a key repeatable finding, central to that research is that THC (Tetrahydrocannabinol) was not a significant contributor to the medicinal and bio-protective aspects of the plant extracts. Rather, it is the other substances (cannabinoids) that are significant active ingredients. THC is illegal in most states and is the ingredient causing one to get “high”. This finding openes the door for innovation and market success, and for ProCannas to legally develop, patent, protect and offer to the market a proprietary non-THC based Cannatrol™ formulation called Cannatrol DM, which is far less regulated by the Administration and FDA (Food and Drug Administration) as supplements, foods, and cosmetics.
Why us?
The primary differences between our non-THC formulations and other non-THC products available on the American are significant. First, we have what we believe to be the only ultra-pure, pharmaceutical grade, maximum strength product available. Second, some of our formulations contain enhancing ingredients and antioxidants such as vitamin C, D3 (Cannatrol VM) and various curcuminoids (Cannatrol TL). To increase absorption, we offer a formulation with bioperine (Cannatrol AB).
We do manufacture a version containing maximum strength THC, and these will be made available only through our participating physicians and only where not prohibited by law.
Apr 7, 2014 PIHN Announces Procannas' Cannabinoid Transdermal Product Development Press Release
Apr 1, 2014 PIHN Hires New Medical Director to Start International Clinical Trials Press Release
Mar 20, 2014 Polaris International Holdings Signs Agreement With India Based Affiliates and Secures New Offices Press Release
Mar 19, 2014 PIHN Signs Exclusive Rights to ProCannas(R) Cannabinoid Line Press Release
finance.yahoo.com/q/h?s=PIHN+Headlines
Disclaimer:
This email and the content provided is intended for advertisement purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our e-mail list. PLEASE NOTE: Marketwire Press employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at marketwirepress.com/disclaimer.php Release of Liability: Through use of this website/newsletter viewing or using you agree to hold marketwirepress.com its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Marketwirepress.com’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Marketwirepress.com encourages readers and investors to supplement the information in these reports with independent research and other pro advice. All information on featured companies is provided by the companies profiled, or is available from public sources and marketwirepress.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Marketwirepress.com often receives compensation for marketing, awareness and investor relation services, which can be reviewed within our disclaimer. Marketwirepress.com has been compensated $1500 cash for the distribution of this email and/or other marketing services by a non controlling third party. We may or may not hold a position and reserve the right to buy or sell shares at any time, which may positively or negatively affect the price per share. This not a solicitation to buy or sell any securities. Marketwirepress.com, nor any of its affiliates are registered investment advisers or broker dealers. (unsubscribe)